Cargando…
Chronic Drug-Induced Liver Injury: Updates and Future Challenges
Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing effective treatment. About 20% of patients with DI...
Autores principales: | Wang, Qiaoling, Huang, Ang, Wang, Jia-Bo, Zou, Zhengsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982586/ https://www.ncbi.nlm.nih.gov/pubmed/33762948 http://dx.doi.org/10.3389/fphar.2021.627133 |
Ejemplares similares
-
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
por: Fu, Siyu, et al.
Publicado: (2020) -
Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023) -
Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury
por: Yang, Ruiyuan, et al.
Publicado: (2022) -
Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury
por: He, Xian, et al.
Publicado: (2022) -
The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study
por: Li, Zhong-Bin, et al.
Publicado: (2021)